Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Babray Laek"'
Autor:
Iuliia Kovalenko, Tabinda Saleem, Mitali Shah, Sara Seyedroudbari, Konstantin Golubykh, Rimsha Ali, Taaha Mirza, Babray Laek, Ahsan Wahab, Asmi Chattaraj, Ekaterina Proskuriakova, Chandi Garg, Rafiullah Khan
Publikováno v:
Advances in Hematology, Vol 2023 (2023)
Background. Graft-versus-host disease (GVHD) is a potentially fatal complication of allogeneic hematopoietic stem cell transplant. The mainstay of treatment is corticosteroids, which are ineffective in 30–50% of cases. Steroid-refractory GVHD (SR-G
Externí odkaz:
https://doaj.org/article/f5413e37154c4a33ad8c4de78965affb
Autor:
Tabinda Saleem, Iuliia Kovalenko, Babray Laek, Rimsha Ali, Taaha Muddassir Mirza, Asmi Chattaraj, Ahsan Wahab, Asma Tameez, Hafiz Qurashi, Konstantin Golubykh, Martin Cuevas, Wern Lynn Ng, Yijin Wert, Rafiullah Khan
Publikováno v:
Blood. 140:12898-12899
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68680044bc6d010790d5e2d99fecf956
https://doi.org/10.1182/blood-2022-157632
https://doi.org/10.1182/blood-2022-157632
Autor:
Iuliia Kovalenko, Tabinda Saleem, Babray Laek, Rimsha Ali, Taaha Mirza, Asmi Chattaraj, Ahsan Wahab, Asma Tameez, Hafiz Qurashi, Konstantin Golubykh, Martin Cuevas, Wern Lynn Ng, Yijin Wert, Rafiullah Khan
Publikováno v:
Blood. 140:12895-12896
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ad9daec1e20a7ae6d1ff267eead715a
https://doi.org/10.1182/blood-2022-157624
https://doi.org/10.1182/blood-2022-157624
Autor:
Zunairah Shah, Israr Khan, Insija Ilyas Selene, Syed Hamza Bin Waqar, Razwana Khanam, Qurrat-ul-ain Abid, Nayha Tahir, Sanjivani Sathe, Babray Laek, Asmi Chattaraj, Zinath Roksana, Irisha Badu, Faiz Anwer
Publikováno v:
Journal of Clinical Oncology. 40:e20009-e20009
e20009 Background: Despite expanding therapeutic armamentarium of multiple myeloma (MM), it remains an incurable disease. Therefore, there is a need to assess the impact of deeper hematological responses to better gauge treatments in clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0658e00ac338ba40cca6779a65092663
https://doi.org/10.1200/jco.2022.40.16_suppl.e20009
https://doi.org/10.1200/jco.2022.40.16_suppl.e20009
Autor:
Iuliia Kovalenko, Tabinda Saleem, Babray Laek, Rimsha Ali, Taaha Muddassir Mirza, Asmi Chattaraj, Ahsan Wahab, Asma Tamez ud din, Hafiz Qurashi, Konstantin Golubykh, Maidah Malik, Rafiullah Khan
Publikováno v:
Journal of Clinical Oncology. 40:e19053-e19053
e19053 Background: Ruxolitinib, an elective Janus Kinase (JAK) 1/2 inhibitor, has been approved by FDA for the treatment of steroid-refractory chronic graft-versus-host-disease (SR cGVHD) after the failure of one or two lines of systemic therapy in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14b0183651b350c39a7c8c737cd81f3c
https://doi.org/10.1200/jco.2022.40.16_suppl.e19053
https://doi.org/10.1200/jco.2022.40.16_suppl.e19053
Autor:
David A. Bluemke, Michael Y. Tsai, Russell P. Tracy, Kunihiro Matsushita, Robyn L. McClelland, Babray Laek, Moyses Szklo, Jingzhong Ding
Previous basic and cross-sectional studies obtained conflicting results regarding the association of pathogens with coronary artery calcium (CAC). The aim of this study is to prospectively evaluate this association in a population-based cohort.We exa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::586bd01a2788e19382c7291c20b22120
https://europepmc.org/articles/PMC3815605/
https://europepmc.org/articles/PMC3815605/
